Compare DY & RDY Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | DY | RDY |
|---|---|---|
| Founded | 1969 | 1984 |
| Country | United States | India |
| Employees | N/A | N/A |
| Industry | Water Sewer Pipeline Comm & Power Line Construction | Biotechnology: Pharmaceutical Preparations |
| Sector | Industrials | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 10.4B | 11.6B |
| IPO Year | 1995 | 2001 |
| Metric | DY | RDY |
|---|---|---|
| Price | $410.31 | $13.08 |
| Analyst Decision | Strong Buy | Strong Buy |
| Analyst Count | 10 | 1 |
| Target Price | ★ $425.30 | $16.90 |
| AVG Volume (30 Days) | 362.6K | ★ 2.1M |
| Earning Date | 05-20-2026 | 05-08-2026 |
| Dividend Yield | N/A | ★ 0.54% |
| EPS Growth | ★ 20.71 | N/A |
| EPS | ★ 9.56 | N/A |
| Revenue | N/A | N/A |
| Revenue This Year | $30.96 | $7.72 |
| Revenue Next Year | $9.49 | $3.50 |
| P/E Ratio | $41.85 | ★ $18.67 |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $150.29 | $12.82 |
| 52 Week High | $445.53 | $16.17 |
| Indicator | DY | RDY |
|---|---|---|
| Relative Strength Index (RSI) | 67.07 | 41.33 |
| Support Level | $331.58 | $12.93 |
| Resistance Level | $445.53 | $14.14 |
| Average True Range (ATR) | 13.33 | 0.25 |
| MACD | 6.32 | 0.00 |
| Stochastic Oscillator | 96.15 | 22.69 |
Dycom Industries Inc is a provider of specialty contracting services to the telecommunications infrastructure and utility industries throughout the United States. The company has two reporting segments: Communications and Building Systems. The Communications segment provides specialty contracting services, including program management, planning; engineering and design; aerial, underground, and wireless construction; maintenance; and fulfillment services for telecommunications and digital infrastructure providers. The Building Systems segment specializes in providing comprehensive building infrastructure solutions, including electrical, energy management, security, and fire safety systems for data centers and other critical facilities. The firm generates key revenue from Communications.
Dr. Reddy's is one of the largest generic drug manufacturers in the world. It has a significant presence in North America, a region that makes up roughly half of its generics sales, and it services India (about 20% of its generics sales), Russia (10%), and certain European and Latin American countries. Beyond simple generics, Dr. Reddy's also has a solid portfolio of injectables which make up 25% of its North America sales. In branded generic markets like India, Dr. Reddy's has established a compelling presence with its strong brand name and earned a top five spot in key therapeutic areas including oncology and gastroenterology. Dr. Reddy's also has an active pharmaceutical ingredient business that manufactures over 150 APIs and sells in over 75 countries.